D. Boral Capital Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) had its price target decreased by analysts at D. Boral Capital from $3.00 to $2.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. D. Boral Capital’s price objective would suggest a potential upside of 212.01% from the […]
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) had its price target decreased by analysts at D. Boral Capital from $3.00 to $2.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. D. Boral Capital’s price objective would suggest a potential upside of 212.01% from the […]
